1.90
Voyager Therapeutics Inc stock is traded at $1.90, with a volume of 573.19K.
It is down -7.77% in the last 24 hours and down -37.70% over the past month.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
See More
Previous Close:
$2.06
Open:
$2.05
24h Volume:
573.19K
Relative Volume:
0.64
Market Cap:
$117.07M
Revenue:
$40.37M
Net Income/Loss:
$-119.72M
P/E Ratio:
-0.9313
EPS:
-2.0402
Net Cash Flow:
$-135.06M
1W Performance:
-22.45%
1M Performance:
-37.70%
6M Performance:
-52.02%
1Y Performance:
-64.35%
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
VYGR
Voyager Therapeutics Inc
|
1.90 | 117.07M | 40.37M | -119.72M | -135.06M | -2.0402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky - Simply Wall Street
Wave Life Sciences Ltd. (WVE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Abeona Therapeutics Inc. (ABEO) stock price, news, quote and history - Yahoo Finance UK
Voyager Technologies, Inc. Prices $350.0 Million Convertible Senior Notes Offering - Yahoo Finance
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes - Yahoo Finance
A $350 million raise could help Voyager expand and buy companies - Stock Titan
Protara Therapeutics (Nasdaq:TARA)Stock Analysis - Simply Wall Street
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Voyager Therapeutics at wells fargo healthcare conference: key data ahead By Investing.com - Investing.com Nigeria
Voyager Therapeutics at wells fargo healthcare conference: key data ahead - Investing.com
Voyager Therapeutics at wells fargo healthcare conference: key data ahead By Investing.com - Investing.com Canada
Voyager Therapeutics stock holds steady as investors watch gene therapy pipeline - ad-hoc-news.de
Voyager to Present at Upcoming Investor Conferences - markets.businessinsider.com
Voyager to Present at Upcoming Investor Conferences - GlobeNewswire
Transcript : Voyager Therapeutics, Inc.Special Call - marketscreener.com
Voyager Therapeutics Inc. (VYGR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Voyager Therapeutics (VYGR) Rises 2.3% as Gene Therapy Stock Approaches Key Resistance at $3.72Composite Profile - siam.in
Voyager Therapeutics (VYGR) Rises 2.3% as Gene Therapy Stock Approaches Key Resistance at $3.72Key Reversal Day - dars.gov.et
Voyager Therapeutics (VYGR) Rises 2.3% as Gene Therapy Stock Approaches Key Resistance at $3.72Diamond Pattern - dars.gov.et
Voyager Therapeutics Inc. (VYGR) Peer Comparison – Compare with Others - Value Research
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy - Investing.com
Voyager Therapeutics (NasdaqGS:VYGR) Stock Forecast & Analyst Predictions - Simply Wall Street
Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Voyager Technologies (VOYG) opens flexible shelf to issue stock, debt and warrants - Stock Titan
Voyager Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | VT6 | US92915B1061 - marketscreener.com
Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares - Stock Titan
Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones - NeurologyLive
Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist - TipRanks
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - simplywall.st
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - simplywall.st
HC Wainwright Brokers Raise Earnings Estimates for VYGR - MarketBeat
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Teleflex (TFX) - The Globe and Mail
Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat
VYGR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - moomoo.com
The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist - Sahm
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates - Investing.com Nigeria
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Is Voyager Therapeutics Inc (VYGR) Overvalued After Q2 Earnings - GuruFocus
Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results - MarketBeat
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates - Investing.com
VYGR Looks 86.3% Overvalued on GF Value™ - GuruFocus
Voyager Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
Voyager Therapeutics: Q2 Earnings Snapshot - KHOU
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Voyager Therapeutics Inc Stock (VYGR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jorgensen Nathan D. | Former Officer |
May 15 '26 |
Proposed Sale |
4.24 |
9,406 |
39,881 |
0 |
| Sandrock Alfred | President and CEO |
Apr 02 '26 |
Sale |
3.87 |
11,511 |
44,548 |
472,549 |
| Sandrock Alfred | Officer |
Apr 02 '26 |
Proposed Sale |
3.87 |
11,511 |
44,597 |
0 |
| Swartz Robin | COO & CBO |
Feb 24 '26 |
Sale |
3.77 |
6,458 |
24,347 |
199,738 |
| Sandrock Alfred | President and CEO |
Feb 24 '26 |
Sale |
3.79 |
14,197 |
53,807 |
484,060 |
| Jorgensen Nathan D. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.77 |
4,668 |
17,598 |
151,416 |
| Carter Todd Alfred | Chief Scientific Officer |
Feb 24 '26 |
Sale |
3.76 |
4,174 |
15,694 |
145,718 |
| Carter Todd Alfred | Officer |
Feb 24 '26 |
Proposed Sale |
3.76 |
4,174 |
15,711 |
0 |
| Jorgensen Nathan D. | Officer |
Feb 24 '26 |
Proposed Sale |
3.77 |
4,668 |
17,588 |
0 |
| Swartz Robin | Officer |
Feb 24 '26 |
Proposed Sale |
3.77 |
6,458 |
24,335 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):